<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34207859</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>09</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Skeletal Muscle Metabolism: Origin or Prognostic Factor for Amyotrophic Lateral Sclerosis (ALS) Development?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1449</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells10061449</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive and selective loss of motor neurons, amyotrophy and skeletal muscle paralysis usually leading to death due to respiratory failure. While generally considered an intrinsic motor neuron disease, data obtained in recent years, including our own, suggest that motor neuron protection is not sufficient to counter the disease. The dismantling of the neuromuscular junction is closely linked to chronic energy deficit found throughout the body. Metabolic (hypermetabolism and dyslipidemia) and mitochondrial alterations described in patients and murine models of ALS are associated with the development and progression of disease pathology and they appear long before motor neurons die. It is clear that these metabolic changes participate in the pathology of the disease. In this review, we summarize these changes seen throughout the course of the disease, and the subsequent impact of glucose-fatty acid oxidation imbalance on disease progression. We also highlight studies that show that correcting this loss of metabolic flexibility should now be considered a major goal for the treatment of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quessada</LastName><ForeName>Cyril</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes Centraux et P&#xe9;riph&#xe9;riques de la Neurod&#xe9;g&#xe9;n&#xe9;rescence, INSERM, UMR_S 1118, Centre de Recherche de Biom&#xe9;decine de Strasbourg (CRBS), Universit&#xe9; de Strasbourg, F-67000 Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouscary</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes Centraux et P&#xe9;riph&#xe9;riques de la Neurod&#xe9;g&#xe9;n&#xe9;rescence, INSERM, UMR_S 1118, Centre de Recherche de Biom&#xe9;decine de Strasbourg (CRBS), Universit&#xe9; de Strasbourg, F-67000 Strasbourg, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuro-Sys SAS, F-13120 Gardanne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren&#xe9;</LastName><ForeName>Fr&#xe9;d&#xe9;rique</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes Centraux et P&#xe9;riph&#xe9;riques de la Neurod&#xe9;g&#xe9;n&#xe9;rescence, INSERM, UMR_S 1118, Centre de Recherche de Biom&#xe9;decine de Strasbourg (CRBS), Universit&#xe9; de Strasbourg, F-67000 Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valle</LastName><ForeName>Cristiana</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0914-6511</Identifier><AffiliationInfo><Affiliation>IRCCS Fondazione Santa Lucia, Institute of Translational Pharmacology, CNR, 00133 Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferri</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Santa Lucia, Institute of Translational Pharmacology, CNR, 00133 Roma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngo</LastName><ForeName>Shyuan T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Research, The University of Queensland, Herston, QLD 4006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queensland Brain Institute, The University of Queensland, St. Lucia, QLD 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loeffler</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes Centraux et P&#xe9;riph&#xe9;riques de la Neurod&#xe9;g&#xe9;n&#xe9;rescence, INSERM, UMR_S 1118, Centre de Recherche de Biom&#xe9;decine de Strasbourg (CRBS), Universit&#xe9; de Strasbourg, F-67000 Strasbourg, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">PDK4</Keyword><Keyword MajorTopicYN="N">hypermetabolism</Keyword><Keyword MajorTopicYN="N">metabolic imbalance</Keyword><Keyword MajorTopicYN="N">neuromuscular junction</Keyword><Keyword MajorTopicYN="N">skeletal muscle</Keyword><Keyword MajorTopicYN="N">trimetazidine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>2</Day><Hour>1</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34207859</ArticleId><ArticleId IdType="pmc">PMC8226541</ArticleId><ArticleId IdType="doi">10.3390/cells10061449</ArticleId><ArticleId IdType="pii">cells10061449</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland L.P., Shneider N.A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2001:13. doi: 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic Lateral Sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Mansfield C., Moussy A., Hermine O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Front. Aging Neurosci. 2017;9 doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic Lateral Sclerosis: A Clinical Review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Couratier P., Corcia P., Lautrette G., Nicol M., Preux P.-M., Marin B. Epidemiology of Amyotrophic Lateral Sclerosis: A Review of Literature. Rev. Neurol. 2016;172:37&#x2013;45. doi: 10.1016/j.neurol.2015.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2015.11.002</ArticleId><ArticleId IdType="pubmed">26727307</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Chi&#xf2; A., Traynor B.J. State of Play in Amyotrophic Lateral Sclerosis Genetics. Nat. Neurosci. 2014;17:17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Sim&#xf3;n-S&#xe1;nchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S., Salachas F., Cazeneuve C., Gordon P., Bricka B., Camuzat A., Guillot-Noel L., Russaouen O., Bruneteau G., Pradat P.-F., et al. SOD1, ANG, VAPB, TARDBP, and FUS Mutations in Familial Amyotrophic Lateral Sclerosis: Genotype-Phenotype Correlations. J. Med. Genet. 2010;47:554&#x2013;560. doi: 10.1136/jmg.2010.077180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2010.077180</ArticleId><ArticleId IdType="pubmed">20577002</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S., Boill&#xe9;e S., Le Ber I., Seilhean D., Teyssou E., Giraudeau M., Moigneu C., Vandenberghe N., Danel-Brunaud V., Corcia P., et al. Phenotype Difference between ALS Patients with Expanded Repeats in C9ORF72 and Patients with Mutations in Other ALS-Related Genes. J. Med. Genet. 2012;49:258&#x2013;263. doi: 10.1136/jmedgenet-2011-100699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2011-100699</ArticleId><ArticleId IdType="pubmed">22499346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J., Bosco D.A., LeClerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., et al. Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis. Science. 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortobagyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K. Safety and Efficacy of Edaravone in Well Defined Patients with Amyotrophic Lateral Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Neurol. 2017;16:8. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J., Ludolph A.C., Huebers A. Disease-Modifying and Symptomatic Treatment of Amyotrophic Lateral Sclerosis. Adv. Neurol. Disord. 2018;11:1756285617734734. doi: 10.1177/1756285617734734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285617734734</ArticleId><ArticleId IdType="pmc">PMC5784546</ArticleId><ArticleId IdType="pubmed">29399045</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber S.C., Shaw P.J. Oxidative Stress in ALS: Key Role in Motor Neuron Injury and Therapeutic Target. Free Radic. Biol. Med. 2010;48:629&#x2013;641. doi: 10.1016/j.freeradbiomed.2009.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.11.018</ArticleId><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer-Hayes L.R., Brotherton T., Glass J.D. Axonal Degeneration in the Peripheral Nervous System: Implications for the Pathogenesis of Amyotrophic Lateral Sclerosis. Exp. Neurol. 2013;246:6&#x2013;13. doi: 10.1016/j.expneurol.2013.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.05.001</ArticleId><ArticleId IdType="pubmed">23664960</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S.-C., Polymenidou M., Cleveland D.W. Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis A.M., Groen E.J.N., Koppers M., van den Berg L.H., Pasterkamp R.J. Protein Aggregation in Amyotrophic Lateral Sclerosis. Acta. Neuropathol. 2013;125:777&#x2013;794. doi: 10.1007/s00401-013-1125-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1125-6</ArticleId><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogaert E., d&#x2019;Ydewalle C., Van Den Bosch L. Amyotrophic Lateral Sclerosis and Excitotoxicity: From Pathological Mechanism to Therapeutic Target. CNSNDDT. 2010;9:297&#x2013;304. doi: 10.2174/187152710791292576.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152710791292576</ArticleId><ArticleId IdType="pubmed">20406181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzolino M., Carr&#xec; M.T. Mitochondrial Dysfunction in ALS. Prog. Neurobiol. 2012;97:54&#x2013;66. doi: 10.1016/j.pneurobio.2011.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2011.06.003</ArticleId><ArticleId IdType="pubmed">21827820</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A., Kim S., Pant B. Amyotrophic Lateral Sclerosis (ALS): A Phylogenetic Disease of the Corticomotoneuron? Muscle Nerve. 1992;15:219&#x2013;224. doi: 10.1002/mus.880150215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880150215</ArticleId><ArticleId IdType="pubmed">1549143</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A., Braak H., Del Tredici K., Lemon R., Ludolph A.C., Kiernan M.C. Cortical Influences Drive Amyotrophic Lateral Sclerosis. J. Neurol. Neurosurg. Psychiatry. 2017;88:917&#x2013;924. doi: 10.1136/jnnp-2017-315573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315573</ArticleId><ArticleId IdType="pubmed">28710326</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunet A., Stuart-Lopez G., Burg T., Scekic-Zahirovic J., Rouaux C. Cortical Circuit Dysfunction as a Potential Driver of Amyotrophic Lateral Sclerosis. Front. Neurosci. 2020;14:363. doi: 10.3389/fnins.2020.00363.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00363</ArticleId><ArticleId IdType="pmc">PMC7201269</ArticleId><ArticleId IdType="pubmed">32410944</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M., Melamed E., Offen D. The &#x201c;Dying-Back&#x201d; Phenomenon of Motor Neurons in ALS. J. Mol. Neurosci. 2011;43:470&#x2013;477. doi: 10.1007/s12031-010-9467-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-010-9467-1</ArticleId><ArticleId IdType="pubmed">21057983</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney E.B., de Winter F., Verhaagen J. ALS as a Distal Axonopathy: Molecular Mechanisms Affecting Neuromuscular Junction Stability in the Presymptomatic Stages of the Disease. Front. Neurosci. 2014;8 doi: 10.3389/fnins.2014.00252.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2014.00252</ArticleId><ArticleId IdType="pmc">PMC4132373</ArticleId><ArticleId IdType="pubmed">25177267</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A., Glass J.D. Amyotrophic Lateral Sclerosis Is a Distal Axonopathy: Evidence in Mice and Man. Exp. Neurol. 2004;185:232&#x2013;240. doi: 10.1016/j.expneurol.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez de Aguilar J.-L., Niederhauser-Wiederkehr C., Halter B., De Tapia M., Di Scala F., Demougin P., Dupuis L., Primig M., Meininger V., Loeffler J.-P. Gene Profiling of Skeletal Muscle in an Amyotrophic Lateral Sclerosis Mouse Model. Physiol. Genom. 2008;32:207&#x2013;218. doi: 10.1152/physiolgenomics.00017.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.00017.2007</ArticleId><ArticleId IdType="pubmed">18000159</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsujihata M., Hazama R., Yoshimura T., Satoh A., Mori M., Nagataki S. The Motor End-Plate Fine Structure and Ultrastructural Localization of Acetylcholine Receptors in Amyotrophic Lateral Sclerosis. Muscle Nerve. 1984;7:243&#x2013;249. doi: 10.1002/mus.880070310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880070310</ArticleId><ArticleId IdType="pubmed">6708970</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikl&#xf3;s L., Engelhardt J., Harati Y., Smith R.G., Jo&#xf3; F., Appel S.H. Ultrastructural Evidence for Altered Calcium in Motor Nerve Terminals in Amyotrophc Lateral Sclerosis: Calcium in ALS Motor Nerve Terminals. Ann. Neurol. 1996;39:203&#x2013;216. doi: 10.1002/ana.410390210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410390210</ArticleId><ArticleId IdType="pubmed">8967752</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A. Detection of Preclinical Motor Neurone Loss in SOD1 Mutation Carriers Using Motor Unit Number Estimation. J. Neurol. Neurosurg. Psychiatry. 2002;73:199&#x2013;201. doi: 10.1136/jnnp.73.2.199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.73.2.199</ArticleId><ArticleId IdType="pmc">PMC1737965</ArticleId><ArticleId IdType="pubmed">12122184</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey D., Schneider C., Xu L., Borg J., Spooren W., Caroni P. Early and Selective Loss of Neuromuscular Synapse Subtypes with Low Sprouting Competence in Motoneuron Diseases. J. Neurosci. 2000;20:2534&#x2013;2542. doi: 10.1523/JNEUROSCI.20-07-02534.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-07-02534.2000</ArticleId><ArticleId IdType="pmc">PMC6772256</ArticleId><ArticleId IdType="pubmed">10729333</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun S., Santos A.F., Saxena S., Xu L., Caroni P. Selective Vulnerability and Pruning of Phasic Motoneuron Axons in Motoneuron Disease Alleviated by CNTF. Nat. Neurosci. 2006;9:408&#x2013;419. doi: 10.1038/nn1653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1653</ArticleId><ArticleId IdType="pubmed">16474388</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinsant S., Mansfield C., Jimenez-Moreno R., Moore V.D.G., Yoshikawa M., Hampton T.G., Prevette D., Caress J., Oppenheim R.W., Milligan C. Characterization of Early Pathogenesis in the SOD1 G93A Mouse Model of ALS: Part II, Results and Discussion. Brain Behav. 2013;3:431&#x2013;457. doi: 10.1002/brb3.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.142</ArticleId><ArticleId IdType="pmc">PMC3869683</ArticleId><ArticleId IdType="pubmed">24381813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo S.T., Baumann F., Ridall P.G., Pettitt A.N., Henderson R.D., Bellingham M.C., McCombe P.A. The Relationship between Bayesian Motor Unit Number Estimation and Histological Measurements of Motor Neurons in Wild-Type and SOD1G93A Mice. Clin. Neurophysiol. 2012;123:2080&#x2013;2091. doi: 10.1016/j.clinph.2012.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2012.01.028</ArticleId><ArticleId IdType="pubmed">22521362</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha M.C., Pousinha P.A., Correia A.M., Sebasti&#xe3;o A.M., Ribeiro J.A. Early Changes of Neuromuscular Transmission in the SOD1(G93A) Mice Model of ALS Start Long before Motor Symptoms Onset. PLoS ONE. 2013;8:e73846. doi: 10.1371/journal.pone.0073846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0073846</ArticleId><ArticleId IdType="pmc">PMC3764017</ArticleId><ArticleId IdType="pubmed">24040091</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould T.W., Buss R.R., Vinsant S., Prevette D., Sun W., Knudson C.M., Milligan C.E., Oppenheim R.W. Complete Dissociation of Motor Neuron Death from Motor Dysfunction by Bax Deletion in a Mouse Model of ALS. J. Neurosci. 2006;26:8774&#x2013;8786. doi: 10.1523/JNEUROSCI.2315-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2315-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674380</ArticleId><ArticleId IdType="pubmed">16928866</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouaux C., Panteleeva I., Rene F., Gonzalez de Aguilar J.-L., Echaniz-Laguna A., Dupuis L., Menger Y., Boutillier A.-L., Loeffler J.-P. Sodium Valproate Exerts Neuroprotective Effects In Vivo through CREB-Binding Protein-Dependent Mechanisms But Does Not Improve Survival in an Amyotrophic Lateral Sclerosis Mouse Model. J. Neurosci. 2007;27:5535&#x2013;5545. doi: 10.1523/JNEUROSCI.1139-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1139-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672753</ArticleId><ArticleId IdType="pubmed">17522299</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Lepore E., Martini M., Barberi L., Nunn A., Scicchitano B.M., Musar&#xf2; A. Metabolic Changes Associated With Muscle Expression of SOD1G93A. Front. Physiol. 2018;9:831. doi: 10.3389/fphys.2018.00831.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.00831</ArticleId><ArticleId IdType="pmc">PMC6048270</ArticleId><ArticleId IdType="pubmed">30042688</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M., Martin L.J. Skeletal Muscle-Restricted Expression of Human SOD1 Causes Motor Neuron Degeneration in Transgenic Mice. Hum. Mol. Genet. 2010;19:2284&#x2013;2302. doi: 10.1093/hmg/ddq106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq106</ArticleId><ArticleId IdType="pmc">PMC2865380</ArticleId><ArticleId IdType="pubmed">20223753</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L.J., Wong M. Skeletal Muscle-Restricted Expression of Human SOD1 in Transgenic Mice Causes a Fatal ALS-Like Syndrome. Front. Neurol. 2020;11 doi: 10.3389/fneur.2020.592851.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.592851</ArticleId><ArticleId IdType="pmc">PMC7767933</ArticleId><ArticleId IdType="pubmed">33381076</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat P.-F., Dubourg O., de Tapia M., di Scala F., Dupuis L., Lenglet T., Bruneteau G., Salachas F., Lacomblez L., Corvol J.-C., et al. Muscle Gene Expression Is a Marker of Amyotrophic Lateral Sclerosis Severity. Neurodegener. Dis. 2012;9:38&#x2013;52. doi: 10.1159/000329723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000329723</ArticleId><ArticleId IdType="pubmed">21934272</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat P.-F., Bruneteau G., Gonzalez de Aguilar J.-L., Dupuis L., Jokic N., Salachas F., Le Forestier N., Echaniz-Laguna A., Dubourg O., Hauw J.-J., et al. Muscle Nogo-a Expression Is a Prognostic Marker in Lower Motor Neuron Syndromes. Ann. Neurol. 2007;62:15&#x2013;20. doi: 10.1002/ana.21122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21122</ArticleId><ArticleId IdType="pubmed">17455292</ArticleId></ArticleIdList></Reference><Reference><Citation>Jokic N., Gonzalez de Aguilar J.-L., Pradat P.-F., Dupuis L., Echaniz-Laguna A., Muller A., Dubourg O., Seilhean D., Hauw J.-J., Loeffler J.-P., et al. Nogo Expression in Muscle Correlates with Amyotrophic Lateral Sclerosis Severity. Ann. Neurol. 2005;57:553&#x2013;556. doi: 10.1002/ana.20420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20420</ArticleId><ArticleId IdType="pubmed">15786457</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Gonzalez de Aguilar J.-L., di Scala F., Rene F., de Tapia M., Pradat P.-F., Lacomblez L., Seihlan D., Prinjha R., Walsh F.S., et al. Nogo Provides a Molecular Marker for Diagnosis of Amyotrophic Lateral Sclerosis. Neurobiol. Dis. 2002;10:358&#x2013;365. doi: 10.1006/nbdi.2002.0522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2002.0522</ArticleId><ArticleId IdType="pubmed">12270696</ArticleId></ArticleIdList></Reference><Reference><Citation>Jokic N., Gonzalez de Aguilar J., Dimou L., Lin S., Fergani A., Ruegg M.A., Schwab M.E., Dupuis L., Loeffler J. The Neurite Outgrowth Inhibitor Nogo-A Promotes Denervation in an Amyotrophic Lateral Sclerosis Model. Embo. Rep. 2006;7:1162&#x2013;1167. doi: 10.1038/sj.embor.7400826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400826</ArticleId><ArticleId IdType="pmc">PMC1679784</ArticleId><ArticleId IdType="pubmed">17039253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowling A.C., Schulz J.B., Brown R.H., Beal M.F. Superoxide Dismutase Activity, Oxidative Damage, and Mitochondrial Energy Metabolism in Familial and Sporadic Amyotrophic Lateral Sclerosis. J. Neurochem. 1993;61:2322&#x2013;2325. doi: 10.1111/j.1471-4159.1993.tb07478.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1993.tb07478.x</ArticleId><ArticleId IdType="pubmed">8245985</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Gonzalez de Aguilar J.-L., Oudart H., de Tapia M., Barbeito L., Loeffler J.-P. Mitochondria in Amyotrophic Lateral Sclerosis: A Trigger and a Target. Neurodegener. Dis. 2004;1:245&#x2013;254. doi: 10.1159/000085063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000085063</ArticleId><ArticleId IdType="pubmed">16908975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S., Horie Y., Iwata M. Mitochondrial Alterations in Dorsal Root Ganglion Cells in Sporadic Amyotrophic Lateral Sclerosis. Acta Neuropathol. 2007;114:633&#x2013;639. doi: 10.1007/s00401-007-0299-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0299-1</ArticleId><ArticleId IdType="pubmed">17929040</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T., De Bock K., Van Den Bosch L. Energy Metabolism in ALS: An Underappreciated Opportunity? Acta. Neuropathol. 2018;135:489&#x2013;509. doi: 10.1007/s00401-018-1835-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1835-x</ArticleId><ArticleId IdType="pmc">PMC5978930</ArticleId><ArticleId IdType="pubmed">29549424</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr&#xec; M.T., D&#x2019;Ambrosi N., Cozzolino M. Pathways to Mitochondrial Dysfunction in ALS Pathogenesis. Biochem. Biophys. Res. Commun. 2017;483:1187&#x2013;1193. doi: 10.1016/j.bbrc.2016.07.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.07.055</ArticleId><ArticleId IdType="pubmed">27416757</ArticleId></ArticleIdList></Reference><Reference><Citation>Vielhaber S., Winkler K., Kirches E., Kunz D., B&#xfc;chner M., Feistner H., Elger C.E., Ludolph A.C., Riepe M.W., Kunz W.S. Visualization of Defective Mitochondrial Function in Skeletal Muscle Fibers of Patients with Sporadic Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 1999;169:133&#x2013;139. doi: 10.1016/S0022-510X(99)00236-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00236-1</ArticleId><ArticleId IdType="pubmed">10540022</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung M.J., Suh Y.-L. Ultrastructural Changes of Mitochondria in the Skeletal Muscle of Patients with Amyotrophic Lateral Sclerosis. Ultrastruct. Pathol. 2002;26:3&#x2013;7. doi: 10.1080/01913120252934260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01913120252934260</ArticleId><ArticleId IdType="pubmed">12028652</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzies F.M. Mitochondrial Dysfunction in a Cell Culture Model of Familial Amyotrophic Lateral Sclerosis. Brain. 2002;125:1522&#x2013;1533. doi: 10.1093/brain/awf167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awf167</ArticleId><ArticleId IdType="pubmed">12077002</ArticleId></ArticleIdList></Reference><Reference><Citation>Crugnola V., Lamperti C., Lucchini V., Ronchi D., Peverelli L., Prelle A., Sciacco M., Bordoni A., Fassone E., Fortunato F., et al. Mitochondrial Respiratory Chain Dysfunction in Muscle from Patients with Amyotrophic Lateral Sclerosis. Arch. Neurol. 2010;67:6. doi: 10.1001/archneurol.2010.128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.128</ArticleId><ArticleId IdType="pubmed">20625092</ArticleId></ArticleIdList></Reference><Reference><Citation>Echaniz-Laguna A., Zoll J., Ponsot E., N&#x2019;Guessan B., Tranchant C., Loeffler J.-P., Lampert E. Muscular Mitochondrial Function in Amyotrophic Lateral Sclerosis Is Progressively Altered as the Disease Develops: A Temporal Study in Man. Exp. Neurol. 2006;198:25&#x2013;30. doi: 10.1016/j.expneurol.2005.07.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2005.07.020</ArticleId><ArticleId IdType="pubmed">16126198</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo G., Yi J., Ma C., Xiao Y., Yi F., Yu T., Zhou J. Defective Mitochondrial Dynamics Is an Early Event in Skeletal Muscle of an Amyotrophic Lateral Sclerosis Mouse Model. PLoS ONE. 2013;8:e82112. doi: 10.1371/journal.pone.0082112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0082112</ArticleId><ArticleId IdType="pmc">PMC3855744</ArticleId><ArticleId IdType="pubmed">24324755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J., Yi J., Fu R., Liu E., Siddique T., R&#xed;os E., Deng H.-X. Hyperactive Intracellular Calcium Signaling Associated with Localized Mitochondrial Defects in Skeletal Muscle of an Animal Model of Amyotrophic Lateral Sclerosis*. J. Biol. Chem. 2010;285:705&#x2013;712. doi: 10.1074/jbc.M109.041319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.041319</ArticleId><ArticleId IdType="pmc">PMC2804218</ArticleId><ArticleId IdType="pubmed">19889637</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemann F.R., Winkler K., Kuznetsov A.V., Bartels C., Vielhaber S., Feistner H., Kunz W.S. Impairment of Mitochondrial Function in Skeletal Muscle of Patients with Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 1998;156:65&#x2013;72. doi: 10.1016/S0022-510X(98)00008-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(98)00008-2</ArticleId><ArticleId IdType="pubmed">9559989</ArticleId></ArticleIdList></Reference><Reference><Citation>Vielhaber S. Mitochondrial DNA Abnormalities in Skeletal Muscle of Patients with Sporadic Amyotrophic Lateral Sclerosis. Brain. 2000;123:1339&#x2013;1348. doi: 10.1093/brain/123.7.1339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/123.7.1339</ArticleId><ArticleId IdType="pubmed">10869047</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza S., Salvatori I., Giacovazzo G., Loeffler J.P., Ren&#xe8; F., Rosina M., Quessada C., Proietti D., Heil C., Rossi S., et al. Skeletal-Muscle Metabolic Reprogramming in ALS-SOD1G93A Mice Predates Disease Onset and Is A Promising Therapeutic Target. iScience. 2020;23:101087. doi: 10.1016/j.isci.2020.101087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101087</ArticleId><ArticleId IdType="pmc">PMC7200935</ArticleId><ArticleId IdType="pubmed">32371370</ArticleId></ArticleIdList></Reference><Reference><Citation>Magran&#xe9; J., Manfredi G. Mitochondrial Function, Morphology, and Axonal Transport in Amyotrophic Lateral Sclerosis. Antioxid. Redox Signal. 2009;11:1615&#x2013;1626. doi: 10.1089/ars.2009.2604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2009.2604</ArticleId><ArticleId IdType="pmc">PMC2789440</ArticleId><ArticleId IdType="pubmed">19344253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M., Zech W.-D., Goos M., Leutbecher C., Ferri A., Zippelius A., Carr&#xec; M., Nau R., Keller B.U. Impairment of Mitochondrial Calcium Handling in a MtSOD1 Cell Culture Model of Motoneuron Disease. BMC Neurosci. 2009;10:64. doi: 10.1186/1471-2202-10-64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-10-64</ArticleId><ArticleId IdType="pmc">PMC2716351</ArticleId><ArticleId IdType="pubmed">19545440</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr&#xec; M.T. Expression of a Cu, Zn Superoxide Dismutase Typical of Familial Amyotrophic Lateral Sclerosis Induces Mitochondrial Alteration and Increase of Cytosolic Ca 2+ Concentration in Transfected Neuroblastoma SH-SY5Y Cells. FEBS Lett. 1997;414:365&#x2013;368. doi: 10.1016/S0014-5793(97)01051-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(97)01051-X</ArticleId><ArticleId IdType="pubmed">9315720</ArticleId></ArticleIdList></Reference><Reference><Citation>Damiano M., Starkov A.A., Petri S., Kipiani K., Kiaei M., Mattiazzi M., Flint Beal M., Manfredi G. Neural Mitochondrial Ca 2+ Capacity Impairment Precedes the Onset of Motor Symptoms in G93A Cu/Zn-Superoxide Dismutase Mutant Mice: Mitochondrial Ca 2+ Capacity in Mutant SOD1 Mice. J. Neurochem. 2006;96:1349&#x2013;1361. doi: 10.1111/j.1471-4159.2006.03619.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.03619.x</ArticleId><ArticleId IdType="pubmed">16478527</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A.E., Boncompagni S., Dirksen R.T. Sarcoplasmic Reticulum-Mitochondrial Symbiosis: Bidirectional Signaling in Skeletal Muscle. Exerc. Sport Sci. Rev. 2009;37:29&#x2013;35. doi: 10.1097/JES.0b013e3181911fa4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JES.0b013e3181911fa4</ArticleId><ArticleId IdType="pmc">PMC2740713</ArticleId><ArticleId IdType="pubmed">19098522</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Sarraj S., King A., Cleveland M., Pradat P.-F., Corse A., Rothstein J.D., Leigh P.N., Abila B., Bates S., Wurthner J., et al. Mitochondrial Abnormalities and Low Grade Inflammation Are Present in the Skeletal Muscle of a Minority of Patients with Amyotrophic Lateral Sclerosis; an Observational Myopathology Study. Acta Neuropathol. Commun. 2014;2:165. doi: 10.1186/s40478-014-0165-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-014-0165-z</ArticleId><ArticleId IdType="pmc">PMC4297389</ArticleId><ArticleId IdType="pubmed">25510661</ArticleId></ArticleIdList></Reference><Reference><Citation>Capitanio D., Vasso M., Ratti A., Grignaschi G., Volta M., Moriggi M., Daleno C., Bendotti C., Silani V., Gelfi C. Molecular Signatures of Amyotrophic Lateral Sclerosis Disease Progression in Hind and Forelimb Muscles of an SOD1 G93A Mouse Model. Antioxid. Redox Signal. 2012;17:1333&#x2013;1350. doi: 10.1089/ars.2012.4524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2012.4524</ArticleId><ArticleId IdType="pmc">PMC3437050</ArticleId><ArticleId IdType="pubmed">22563797</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Scala F., Rene F., Tapia M., Oudart H., Pradat P.-F., Meininger V., Loeffler J.-P. Up-regulation of Mitochondrial Uncoupling Protein 3 Reveals an Early Muscular Metabolic Defect in Amyotrophic Lateral Sclerosis. FASEB J. 2003;17:1&#x2013;19. doi: 10.1096/fj.02-1182fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.02-1182fje</ArticleId><ArticleId IdType="pubmed">14500553</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabben M., Hoeks J. Mitochondrial Uncoupling Protein 3 and Its Role in Cardiac- and Skeletal Muscle Metabolism. Physiol. Behav. 2008;94:259&#x2013;269. doi: 10.1016/j.physbeh.2007.11.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.physbeh.2007.11.039</ArticleId><ArticleId IdType="pubmed">18191161</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguer C., Fiehn O., Seifert E.L., B&#xe9;zaire V., Meissen J.K., Daniels A., Scott K., Renaud J., Padilla M., Bickel D.R., et al. Muscle Uncoupling Protein 3 Overexpression Mimics Endurance Training and Reduces Circulating Biomarkers of Incomplete &#x392;-oxidation. FASEB J. 2013;27:4213&#x2013;4225. doi: 10.1096/fj.13-234302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.13-234302</ArticleId><ArticleId IdType="pmc">PMC4046190</ArticleId><ArticleId IdType="pubmed">23825224</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Gonzalez de Aguilar J.-L., Echaniz-Laguna A., Eschbach J., Rene F., Oudart H., Halter B., Huze C., Schaeffer L., Bouillaud F., et al. Muscle Mitochondrial Uncoupling Dismantles Neuromuscular Junction and Triggers Distal Degeneration of Motor Neurons. PLoS ONE. 2009;4:e5390. doi: 10.1371/journal.pone.0005390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0005390</ArticleId><ArticleId IdType="pmc">PMC2671839</ArticleId><ArticleId IdType="pubmed">19404401</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler J., Picchiarelli G., Dupuis L., Gonzalez De Aguilar J. The Role of Skeletal Muscle in Amyotrophic Lateral Sclerosis. Brain Pathol. 2016;26:227&#x2013;236. doi: 10.1111/bpa.12350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12350</ArticleId><ArticleId IdType="pmc">PMC8029271</ArticleId><ArticleId IdType="pubmed">26780251</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Aucello M., Rizzuto E., Beccafico S., Mammucari C., Bonconpagni S., Belia S., Wannenes F., Nicoletti C., Del Prete Z., et al. Skeletal Muscle Is a Primary Target of SOD1G93A-Mediated Toxicity. Cell Metab. 2008;8:425&#x2013;436. doi: 10.1016/j.cmet.2008.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2008.09.002</ArticleId><ArticleId IdType="pubmed">19046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannides Z.A., Ngo S.T., Henderson R.D., McCombe P.A., Steyn F.J. Altered Metabolic Homeostasis in Amyotrophic Lateral Sclerosis: Mechanisms of Energy Imbalance and Contribution to Disease Progression. Neurodegener. Dis. 2016;16:382&#x2013;397. doi: 10.1159/000446502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000446502</ArticleId><ArticleId IdType="pubmed">27400276</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E.F., Shaw P.J., De Vos K.J. The Role of Mitochondria in Amyotrophic Lateral Sclerosis. Neurosci. Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G.H., Kim J.E., Rhie S.J., Yoon S. The Role of Oxidative Stress in Neurodegenerative Diseases. Exp. Neurobiol. 2015;24:325&#x2013;340. doi: 10.5607/en.2015.24.4.325.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2015.24.4.325</ArticleId><ArticleId IdType="pmc">PMC4688332</ArticleId><ArticleId IdType="pubmed">26713080</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S., Abramov A.Y. Mechanism of Oxidative Stress in Neurodegeneration. Oxidative Med. Cell. Longev. 2012;2012:1&#x2013;11. doi: 10.1155/2012/428010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/428010</ArticleId><ArticleId IdType="pmc">PMC3362933</ArticleId><ArticleId IdType="pubmed">22685618</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Keung W., Samokhvalov V., Wang W., Lopaschuk G.D. Role of Fatty Acid Uptake and Fatty Acid &#x3b2;-Oxidation in Mediating Insulin Resistance in Heart and Skeletal Muscle. Biochim. Et Biophys. Acta (BBA)-Mol. Cell Biol. Lipids. 2010;1801:1&#x2013;22. doi: 10.1016/j.bbalip.2009.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2009.09.014</ArticleId><ArticleId IdType="pubmed">19782765</ArticleId></ArticleIdList></Reference><Reference><Citation>Aon M.A., Bhatt N., Cortassa S.C. Mitochondrial and Cellular Mechanisms for Managing Lipid Excess. Front. Physiol. 2014;5 doi: 10.3389/fphys.2014.00282.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2014.00282</ArticleId><ArticleId IdType="pmc">PMC4116787</ArticleId><ArticleId IdType="pubmed">25132820</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber S.C., Mead R.J., Shaw P.J. Oxidative Stress in ALS: A Mechanism of Neurodegeneration and a Therapeutic Target. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 2006;1762:1051&#x2013;1067. doi: 10.1016/j.bbadis.2006.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.03.008</ArticleId><ArticleId IdType="pubmed">16713195</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney D.J., Kaczor J.J., Bourgeois J., Yasuda N., Tarnopolsky M.A. Oxidative Stress and Antioxidant Enzyme Upregulation in SOD1-G93A Mouse Skeletal Muscle. Muscle Nerve. 2006;33:809&#x2013;816. doi: 10.1002/mus.20542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20542</ArticleId><ArticleId IdType="pubmed">16583367</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.G., Henry Y.K., Mattson M.P., Appel S.H. Presence of 4-Hydroxynonenal in Cerebrospinal Fluid of Patients with Sporadic Amyotrophic Lateral Sclerosis. Ann. Neurol. 1998;44:696&#x2013;699. doi: 10.1002/ana.410440419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410440419</ArticleId><ArticleId IdType="pubmed">9778272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H., Santella R.M., Liu X., Bogdanov M., Zipprich J., Wu H.-C., Mahata J., Kilty M., Bednarz K., Bell D., et al. Oxidative Stress Biomarkers in Sporadic ALS. Amyotroph. Lateral Scler. 2008;9:177&#x2013;183. doi: 10.1080/17482960801933942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960801933942</ArticleId><ArticleId IdType="pmc">PMC4332387</ArticleId><ArticleId IdType="pubmed">18574762</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P.J., Ince P.G., Falkous G., Mantle D. Oxidative Damage to Protein in Sporadic Motor Neuron Disease Spinal Cord. Ann. Neurol. 1995;38:691&#x2013;695. doi: 10.1002/ana.410380424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380424</ArticleId><ArticleId IdType="pubmed">7574472</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N., Nagai R., Uchida K., Horiuchi S., Yamada S., Hirano A., Kawaguchi M., Yamamoto T., Sasaki S., Kobayashi M. Morphological Evidence for Lipid Peroxidation and Protein Glycoxidation in Spinal Cords from Sporadic Amyotrophic Lateral Sclerosis Patients. Brain Res. 2001;917:97&#x2013;104. doi: 10.1016/S0006-8993(01)02926-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(01)02926-2</ArticleId><ArticleId IdType="pubmed">11602233</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y., Kong Q., Shan X., Tian G., Ilieva H., Cleveland D.W., Rothstein J.D., Borchelt D.R., Wong P.C., Lin C.G. Messenger RNA Oxidation Occurs Early in Disease Pathogenesis and Promotes Motor Neuron Degeneration in ALS. PLoS ONE. 2008;3:e2849. doi: 10.1371/journal.pone.0002849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0002849</ArticleId><ArticleId IdType="pmc">PMC2481395</ArticleId><ArticleId IdType="pubmed">18682740</ArticleId></ArticleIdList></Reference><Reference><Citation>Halter B., Gonzalez de Aguilar J.-L., Rene F., Petri S., Fricker B., Echaniz-Laguna A., Dupuis L., Larmet Y., Loeffler J.-P. Oxidative Stress in Skeletal Muscle Stimulates Early Expression of Rad in a Mouse Model of Amyotrophic Lateral Sclerosis. Free Radic. Biol. Med. 2010;48:915&#x2013;923. doi: 10.1016/j.freeradbiomed.2010.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2010.01.014</ArticleId><ArticleId IdType="pubmed">20079427</ArticleId></ArticleIdList></Reference><Reference><Citation>Leclerc N., Ribera F., Zoll J., Warter J.-M., Poindron P., Lampert E., Borg J. Selective Changes in Mitochondria Respiratory Properties in Oxidative or Glycolytic Muscle Fibers Isolated from G93AhumanSOD1 Transgenic Mice. Neuromuscul. Disord. 2001;11:722&#x2013;727. doi: 10.1016/S0960-8966(01)00240-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-8966(01)00240-1</ArticleId><ArticleId IdType="pubmed">11595514</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Karam C., Yi J., Zhang L., Li X., Yoon D., Wang H., Dhakal K., Ramlow P., Yu T., et al. ROS-Related Mitochondrial Dysfunction in Skeletal Muscle of an ALS Mouse Model during the Disease Progression. Pharmacol. Res. 2018;138:25&#x2013;36. doi: 10.1016/j.phrs.2018.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2018.09.008</ArticleId><ArticleId IdType="pmc">PMC6263743</ArticleId><ArticleId IdType="pubmed">30236524</ArticleId></ArticleIdList></Reference><Reference><Citation>Echaniz-Laguna A., Zoll J., Ribera F., Tranchant C., Warter J.-M., Lonsdorfer J., Lampert E. Mitochondrial Respiratory Chain Function in Skeletal Muscle of ALS Patients. Ann. Neurol. 2002;52:623&#x2013;627. doi: 10.1002/ana.10357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10357</ArticleId><ArticleId IdType="pubmed">12402260</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasnianski A., Deschauer M., Neudecker S., Gellerich F.N., M&#xfc;ller T., Schoser B.G., Krasnianski M., Zierz S. Mitochondrial Changes in Skeletal Muscle in Amyotrophic Lateral Sclerosis and Other Neurogenic Atrophies. Brain. 2005;128:1870&#x2013;1876. doi: 10.1093/brain/awh540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh540</ArticleId><ArticleId IdType="pubmed">15901649</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan T.E., Erickson M.L., Verma A., Chavez J., Rivner M.H., Mccully K.K. Skeletal Muscle Oxidative Capacity in Amyotrophic Lateral Sclerosis: Muscle Metabolism in ALS. Muscle Nerve. 2014;50:767&#x2013;774. doi: 10.1002/mus.24223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24223</ArticleId><ArticleId IdType="pubmed">24616062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis E.J., Berryman S., Vanderleest J.G., Schneider A.R., McClain C.J. Nutritional Status of Patients with Amyotrophic Lateral Sclerosis: Relation to the Proximity of Death. Am. J. Clin. Nutr. 1996;63:130&#x2013;137. doi: 10.1093/ajcn/63.1.130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/63.1.130</ArticleId><ArticleId IdType="pubmed">8604660</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes E.T., Perurena O.H., Festoff B.W., Jorgensen R., Moore W.V. Insulin Resistance in Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 1984;63:317&#x2013;324. doi: 10.1016/0022-510X(84)90154-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(84)90154-0</ArticleId><ArticleId IdType="pubmed">6374040</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat P.-F., Bruneteau G., Gordon P.H., Dupuis L., Bonnefont-Rousselot D., Simon D., Salachas F., Corcia P., Frochot V., Lacorte J.-M., et al. Impaired Glucose Tolerance in Patients with Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. 2010;11:166&#x2013;171. doi: 10.3109/17482960902822960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902822960</ArticleId><ArticleId IdType="pubmed">20184518</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.C., Preux P.M., Truong T.C., Vallat J.M., Sautereau D., Couratier P. Nutritional Status Is a Prognostic Factor for Survival in ALS Patients. Neurology. 1999;53:1059. doi: 10.1212/WNL.53.5.1059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.5.1059</ArticleId><ArticleId IdType="pubmed">10496266</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B., Desport J.C., Kajeu P., Jesus P., Nicolaud B., Nicol M., Preux P.M., Couratier P. Alteration of Nutritional Status at Diagnosis Is a Prognostic Factor for Survival of Amyotrophic Lateral Sclerosis Patients. J. Neurol. Neurosurg. Psychiatry. 2011;82:628&#x2013;634. doi: 10.1136/jnnp.2010.211474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.211474</ArticleId><ArticleId IdType="pubmed">21097551</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakken O., Meyer H.E., Stigum H., Holm&#xf8;y T. High BMI Is Associated with Low ALS Risk: A Population-Based Study. Neurology. 2019;93:e424&#x2013;e432. doi: 10.1212/WNL.0000000000007861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007861</ArticleId><ArticleId IdType="pubmed">31243073</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape J.A., Grose J.H. The Effects of Diet and Sex in Amyotrophic Lateral Sclerosis. Rev. Neurol. 2020;176:301&#x2013;315. doi: 10.1016/j.neurol.2019.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2019.09.008</ArticleId><ArticleId IdType="pubmed">32147204</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A., Murthy S.B., Wilson A.M., Qureshi S.U., Amro M.J., Wheaton M., Simpson E., Harati Y., Strutt A.M., York M.K., et al. A Decrease in Body Mass Index Is Associated with Faster Progression of Motor Symptoms and Shorter Survival in ALS. Amyotroph. Lateral Scler. 2010;11:542&#x2013;548. doi: 10.3109/17482968.2010.482592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.482592</ArticleId><ArticleId IdType="pubmed">20500116</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Deng J., Jaffa M., Cudkowicz M.E., Wills A.-M. Body Mass Index, Not Dyslipidemia, Is an Independent Predictor of Survival in Amyotrophic Lateral Sclerosis. Muscle Nerve. 2011;44:20&#x2013;24. doi: 10.1002/mus.22114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22114</ArticleId><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E., Siokas V., Sokratous M., Tsouris Z., Aloizou A.-M., Florou D., Dastamani M., Mentis A.-F.A., Brotis A.G. Body Mass Index and Survival from Amyotrophic Lateral Sclerosis: A Meta-Analysis. Neurol. Clin. Pract. 2018;8:437&#x2013;444. doi: 10.1212/CPJ.0000000000000521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000000521</ArticleId><ArticleId IdType="pmc">PMC6276330</ArticleId><ArticleId IdType="pubmed">30564498</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly &#xc9;.J., Wang H., Weisskopf M.G., Fitzgerald K.C., Falcone G., McCullough M.L., Thun M., Park Y., Kolonel L.N., Ascherio A. Premorbid Body Mass Index and Risk of Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2013;14:205&#x2013;211. doi: 10.3109/21678421.2012.735240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.735240</ArticleId><ArticleId IdType="pmc">PMC3615420</ArticleId><ArticleId IdType="pubmed">23134505</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.C., Preux P.M., Magy L., Boirie Y., Vallat J.M., Beaufr&#xe8;re B., Couratier P. Factors Correlated with Hypermetabolism in Patients with Amyotrophic Lateral Sclerosis. Am. J. Clin. Nutr. 2001;74:328&#x2013;334. doi: 10.1093/ajcn/74.3.328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/74.3.328</ArticleId><ArticleId IdType="pubmed">11522556</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.-C., Torny F., Lacoste M., Preux P.-M., Couratier P. Hypermetabolism in ALS: Correlations with Clinical and Paraclinical Parameters. Neurodegener. Dis. 2005;2:202&#x2013;207. doi: 10.1159/000089626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000089626</ArticleId><ArticleId IdType="pubmed">16909026</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayemendy P., Marin B., Labrunie A., Boirie Y., Walrand S., Achamrah N., Co&#xeb;ffier M., Preux P.-M., Lautrette G., Desport J.-C., et al. Hypermetabolism Is a Reality in Amyotrophic Lateral Sclerosis Compared to Healthy Subjects. J. Neurol. Sci. 2021;420:117257. doi: 10.1016/j.jns.2020.117257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117257</ArticleId><ArticleId IdType="pubmed">33290920</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe9;sus P., Fayemendy P., Nicol M., Lautrette G., Sourisseau H., Preux P.-M., Desport J.-C., Marin B., Couratier P. Hypermetabolism Is a Deleterious Prognostic Factor in Patients with Amyotrophic Lateral Sclerosis. Eur. J. Neurol. 2018;25:97&#x2013;104. doi: 10.1111/ene.13468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13468</ArticleId><ArticleId IdType="pubmed">28940704</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup C., Desport J.-C., Clavelou P., Guy N., Derumeaux-Burel H., Ferrier A., Couratier P. Hypermetabolism in ALS Patients: An Early and Persistent Phenomenon. J. Neurol. 2009;256:1236&#x2013;1242. doi: 10.1007/s00415-009-5100-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5100-z</ArticleId><ArticleId IdType="pubmed">19306035</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn F.J., Ioannides Z.A., van Eijk R.P.A., Heggie S., Thorpe K.A., Ceslis A., Heshmat S., Henders A.K., Wray N.R., van den Berg L.H., et al. Hypermetabolism in ALS Is Associated with Greater Functional Decline and Shorter Survival. J. Neurol. Neurosurg. Psychiatry. 2018;89:1016&#x2013;1023. doi: 10.1136/jnnp-2017-317887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Funalot B., Desport J.-C., Sturtz F., Camu W., Couratier P. High Metabolic Level in Patients with Familial Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. 2009;10:113&#x2013;117. doi: 10.1080/17482960802295192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802295192</ArticleId><ArticleId IdType="pubmed">18792852</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter R.S., Rosenbohm A., Dupuis L., Brehme T., Kassubek J., Rothenbacher D., Nagel G., Ludolph A.C. Life Course Body Mass Index and Risk and Prognosis of Amyotrophic Lateral Sclerosis: Results from the ALS Registry Swabia. Eur. J. Epidemiol. 2017;32:901&#x2013;908. doi: 10.1007/s10654-017-0318-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-017-0318-z</ArticleId><ArticleId IdType="pubmed">28975435</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C., Calvo A., Grassano M., Canosa A., Manera U., D&#x2019;Ovidio F., Bombaci A., Bersano E., Mazzini L., Mora G., et al. Early Weight Loss in Amyotrophic Lateral Sclerosis: Outcome Relevance and Clinical Correlates in a Population-Based Cohort. J. Neurol. Neurosurg. Psychiatry. 2019;90:666&#x2013;673. doi: 10.1136/jnnp-2018-319611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319611</ArticleId><ArticleId IdType="pubmed">30630957</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Corcia P., Fergani A. Dyslipidemia Is a Protective Factor in Amyotrophic Lateral Sclerosis. Neurology. 2008;7:1004&#x2013;1009. doi: 10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo S.T., Steyn F.J., Huang L., Mantovani S., Pfluger C.M.M., Woodruff T.M., O&#x2019;Sullivan J.D., Henderson R.D., McCombe P.A. Altered Expression of Metabolic Proteins and Adipokines in Patients with Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 2015;357:22&#x2013;27. doi: 10.1016/j.jns.2015.06.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.06.053</ArticleId><ArticleId IdType="pubmed">26198021</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Oudart H., Rene F., de Aguilar J.-L.G., Loeffler J.-P. Evidence for Defective Energy Homeostasis in Amyotrophic Lateral Sclerosis: Benefit of a High-Energy Diet in a Transgenic Mouse Model. Proc. Natl. Acad. Sci. USA. 2004;101:11159&#x2013;11164. doi: 10.1073/pnas.0402026101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402026101</ArticleId><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamiuc L., Schlagowski A., Ngo S.T., Vernay A., Dirrig-Grosch S., Henriques A., Boutillier A., Zoll J., Echaniz-Laguna A., Loeffler J., et al. A Metabolic Switch toward Lipid Use in Glycolytic Muscle Is an Early Pathologic Event in a Mouse Model of Amyotrophic Lateral Sclerosis. Embo. Mol. Med. 2015;7:526&#x2013;546. doi: 10.15252/emmm.201404433.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201404433</ArticleId><ArticleId IdType="pmc">PMC4492815</ArticleId><ArticleId IdType="pubmed">25820275</ArticleId></ArticleIdList></Reference><Reference><Citation>Joardar A., Manzo E., Zarnescu D.C. Metabolic Dysregulation in Amyotrophic Lateral Sclerosis: Challenges and Opportunities. Curr. Genet. Med. Rep. 2017;5:108&#x2013;114. doi: 10.1007/s40142-017-0123-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40142-017-0123-8</ArticleId><ArticleId IdType="pmc">PMC5647833</ArticleId><ArticleId IdType="pubmed">29057168</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeoung N.H., Wu P., Joshi M.A., Jaskiewicz J., Bock C.B., Depaoli-Roach A.A., Harris R.A. Role of Pyruvate Dehydrogenase Kinase Isoenzyme 4 (PDHK4) in Glucose Homoeostasis during Starvation. Biochem. J. 2006;397:417&#x2013;425. doi: 10.1042/BJ20060125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20060125</ArticleId><ArticleId IdType="pmc">PMC1533314</ArticleId><ArticleId IdType="pubmed">16606348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Hulver M.W., McMillan R.P., Cline M.A., Gilbert E.R. The Pivotal Role of Pyruvate Dehydrogenase Kinases in Metabolic Flexibility. Nutr. Metab. (Lond.) 2014;11:10. doi: 10.1186/1743-7075-11-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-7075-11-10</ArticleId><ArticleId IdType="pmc">PMC3925357</ArticleId><ArticleId IdType="pubmed">24520982</ArticleId></ArticleIdList></Reference><Reference><Citation>Desseille C., Deforges S., Biondi O., Houdebine L., D&#x2019;amico D., Lamazi&#xe8;re A., Caradeuc C., Bertho G., Bruneteau G., Weill L., et al. Specific Physical Exercise Improves Energetic Metabolism in the Skeletal Muscle of Amyotrophic-Lateral- Sclerosis Mice. Front. Mol. Neurosci. 2017;10:332. doi: 10.3389/fnmol.2017.00332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00332</ArticleId><ArticleId IdType="pmc">PMC5655117</ArticleId><ArticleId IdType="pubmed">29104532</ArticleId></ArticleIdList></Reference><Reference><Citation>Telerman-Toppet N., Co&#xeb;rs C. Motor Innervation and Fiber Type Pattern in Amyotrophic Lateral Sclerosis and in Charcot-Marie-Tooth Disease: Motor Units in ALS and CMT. Muscle Nerve. 1978;1:133&#x2013;139. doi: 10.1002/mus.880010205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880010205</ArticleId><ArticleId IdType="pubmed">155778</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegedus J., Putman C.T., Gordon T. Time Course of Preferential Motor Unit Loss in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. Neurobiol. Dis. 2007;28:154&#x2013;164. doi: 10.1016/j.nbd.2007.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2007.07.003</ArticleId><ArticleId IdType="pubmed">17766128</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegedus J., Putman C.T., Tyreman N., Gordon T. Preferential Motor Unit Loss in the SOD1 G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis: Motor Units in Mouse ALS. J. Physiol. 2008;586:3337&#x2013;3351. doi: 10.1113/jphysiol.2007.149286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2007.149286</ArticleId><ArticleId IdType="pmc">PMC2538809</ArticleId><ArticleId IdType="pubmed">18467368</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkin J.D., Scott R.L., West J.M., Lopes E., Quah A.K.J., Cheema S.S. Properties of Slow- and Fast-Twitch Muscle Fibres in a Mouse Model of Amyotrophic Lateral Sclerosis. Neuromuscul. Disord. 2005;15:377&#x2013;388. doi: 10.1016/j.nmd.2005.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2005.02.005</ArticleId><ArticleId IdType="pubmed">15833433</ArticleId></ArticleIdList></Reference><Reference><Citation>Deforges S., Branchu J., Biondi O., Grondard C., Pariset C., L&#xe9;colle S., Lopes P., Vidal P.-P., Chanoine C., Charbonnier F. Motoneuron Survival Is Promoted by Specific Exercise in a Mouse Model of Amyotrophic Lateral Sclerosis: Motoneuron Activation and Neuroprotection in ALS Mice. J. Physiol. 2009;587:3561&#x2013;3572. doi: 10.1113/jphysiol.2009.169748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2009.169748</ArticleId><ArticleId IdType="pmc">PMC2742281</ArticleId><ArticleId IdType="pubmed">19491245</ArticleId></ArticleIdList></Reference><Reference><Citation>Flis D.J., Dzik K., Kaczor J.J., Cieminski K., Halon-Golabek M., Antosiewicz J., Wieckowski M.R., Ziolkowski W. Swim Training Modulates Mouse Skeletal Muscle Energy Metabolism and Ameliorates Reduction in Grip Strength in a Mouse Model of Amyotrophic Lateral Sclerosis. IJMS. 2019;20:233. doi: 10.3390/ijms20020233.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20020233</ArticleId><ArticleId IdType="pmc">PMC6359093</ArticleId><ArticleId IdType="pubmed">30634386</ArticleId></ArticleIdList></Reference><Reference><Citation>Randle P.J., Garland P.B., Hales C.N., Newsholme E.A. The Glucose Fatty-Acid Cycle. Its Role in Insulin Sensitivity and the Metabolic Disturbances of Diabetes Mellitus. Lancet. 1963;1:785&#x2013;789. doi: 10.1016/S0140-6736(63)91500-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(63)91500-9</ArticleId><ArticleId IdType="pubmed">13990765</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassel-Duby R., Olson E.N. Signaling Pathways in Skeletal Muscle Remodeling. Annu. Rev. Biochem. 2006;75:19&#x2013;37. doi: 10.1146/annurev.biochem.75.103004.142622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.75.103004.142622</ArticleId><ArticleId IdType="pubmed">16756483</ArticleId></ArticleIdList></Reference><Reference><Citation>Talanian J.L., Holloway G.P., Snook L.A., Heigenhauser G.J.F., Bonen A., Spriet L.L. Exercise Training Increases Sarcolemmal and Mitochondrial Fatty Acid Transport Proteins in Human Skeletal Muscle. Endocrinol. Metab. 2010;299:9. doi: 10.1152/ajpendo.00073.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00073.2010</ArticleId><ArticleId IdType="pubmed">20484014</ArticleId></ArticleIdList></Reference><Reference><Citation>Pette D., Staron R.S. Transitions of Muscle Fiber Phenotypic Profiles. Histochem Cell Biol. 2001;115:359&#x2013;372. doi: 10.1007/s004180100268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004180100268</ArticleId><ArticleId IdType="pubmed">11449884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacorte E., Ferrigno L., Leoncini E., Corbo M., Boccia S., Vanacore N. Physical Activity, and Physical Activity Related to Sports, Leisure and Occupational Activity as Risk Factors for ALS: A Systematic Review. Neurosci. Biobehav. Rev. 2016;66:61&#x2013;79. doi: 10.1016/j.neubiorev.2016.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2016.04.007</ArticleId><ArticleId IdType="pubmed">27108217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzoni V. Amyotrophic Lateral Sclerosis and Environmental Factors. Funct. Neurol. 2016;31 doi: 10.11138/FNeur/2016.31.1.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.11138/FNeur/2016.31.1.007</ArticleId><ArticleId IdType="pmc">PMC4819821</ArticleId><ArticleId IdType="pubmed">27027889</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A. Severely Increased Risk of Amyotrophic Lateral Sclerosis among Italian Professional Football Players. Brain. 2005;128:472&#x2013;476. doi: 10.1093/brain/awh373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh373</ArticleId><ArticleId IdType="pubmed">15634730</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Mora G., Calvo A., Mazzini L., Bottacchi E., Mutani R. On behalf of the PARALS Epidemiology of ALS in Italy: A 10-Year Prospective Population-Based Study. Neurology. 2009;72:725&#x2013;731. doi: 10.1212/01.wnl.0000343008.26874.d1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000343008.26874.d1</ArticleId><ArticleId IdType="pubmed">19237701</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E. Are Professional Soccer Players at Higher Risk for ALS? Amyotroph. Lateral Scler. Front. Degener. 2013;14:501&#x2013;506. doi: 10.3109/21678421.2013.809764.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.809764</ArticleId><ArticleId IdType="pubmed">23859483</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazza O., Sir&#xe9;n A.-L., Ehrenreich H. Soccer, Neurotrauma and Amyotrophic Lateral Sclerosis: Is There a Connection? Curr. Med. Res. Opin. 2004;20:505&#x2013;508. doi: 10.1185/030079904125003296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/030079904125003296</ArticleId><ArticleId IdType="pubmed">15119987</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Hardiman O. The Epidemiology of ALS: A Conspiracy of Genes, Environment and Time. Nat. Rev. Neurol. 2013;9:617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N., Shih T., Stern Y., Ottman R., Rowland L.P. Premorbid Weight, Body Mass, and Varsity Athletics in ALS. Neurology. 2002;59:773&#x2013;775. doi: 10.1212/WNL.59.5.773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.59.5.773</ArticleId><ArticleId IdType="pubmed">12221178</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman M.H.B., Seelen M., de Jong S.W., Dorresteijn K.R.I.S., van Doormaal P.T.C., van der Kooi A.J., de Visser M., Schelhaas H.J., van den Berg L.H., Veldink J.H. Lifetime Physical Activity and the Risk of Amyotrophic Lateral Sclerosis. J. Neurol. Neurosurg. Psychiatry. 2013;84:976&#x2013;981. doi: 10.1136/jnnp-2012-304724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304724</ArticleId><ArticleId IdType="pubmed">23418211</ArticleId></ArticleIdList></Reference><Reference><Citation>Longstreth W.T., McGuire V., Koepsell T.D., Wang Y., van Belle G. Risk of Amyotrophic Lateral Sclerosis and History of Physical Activity: A Population-Based Case-Control Study. Arch Neurol. 1998;55:201. doi: 10.1001/archneur.55.2.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.55.2.201</ArticleId><ArticleId IdType="pubmed">9482362</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenti M., Pontieri F.E., Conti F., Altobelli E., Manzoni T., Frati L. Amyotrophic Lateral Sclerosis and Sports: A Case-Control Study. Eur. J. Neurol. 2005;12:223&#x2013;225. doi: 10.1111/j.1468-1331.2004.00978.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2004.00978.x</ArticleId><ArticleId IdType="pubmed">15693813</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Goldacre R., Ramagopalan S., Talbot K., Goldacre M.J. Autoimmune Disease Preceding Amyotrophic Lateral Sclerosis: An Epidemiologic Study. Neurology. 2013;81:1222&#x2013;1225. doi: 10.1212/WNL.0b013e3182a6cc13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a6cc13</ArticleId><ArticleId IdType="pmc">PMC3795611</ArticleId><ArticleId IdType="pubmed">23946298</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Bello-Haas V., Florence J.M. Therapeutic Exercise for People with Amyotrophic Lateral Sclerosis or Motor Neuron Disease. Cochrane Database Syst. Rev. 2013 doi: 10.1002/14651858.CD005229.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005229.pub3</ArticleId><ArticleId IdType="pmc">PMC6769061</ArticleId><ArticleId IdType="pubmed">23728653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney D.J., Rodriguez C., Devries M., Yasuda N., Tarnopolsky M.A. Effects of High-Intensity Endurance Exercise Training in the G93A Mouse Model of Amyotrophic Lateral Sclerosis. Muscle Nerve. 2004;29:656&#x2013;662. doi: 10.1002/mus.20004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20004</ArticleId><ArticleId IdType="pubmed">15116368</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreras I., Yuruker S., Aytan N., Hossain L., Choi J.-K., Jenkins B.G., Kowall N.W., Dedeoglu A. Moderate Exercise Delays the Motor Performance Decline in a Transgenic Model of ALS. Brain Res. 2010;1313:192&#x2013;201. doi: 10.1016/j.brainres.2009.11.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.11.051</ArticleId><ArticleId IdType="pmc">PMC2892864</ArticleId><ArticleId IdType="pubmed">19968977</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar B.K., Frost L.M., Christian L., Umapathi P., Gage F.H. Synergy of Insulin-like Growth Factor-1 and Exercise in Amyotrophic Lateral Sclerosis. Ann. Neurol. 2005;57:649&#x2013;655. doi: 10.1002/ana.20451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20451</ArticleId><ArticleId IdType="pubmed">15852403</ArticleId></ArticleIdList></Reference><Reference><Citation>Grondard C., Biondi O., Pariset C., Lopes P., Deforges S., L&#xe9;colle S., Gaspera B.D., Gallien C.-L., Chanoine C., Charbonnier F. Exercise-Induced Modulation of Calcineurin Activity Parallels the Time Course of Myofibre Transitions. J. Cell. Physiol. 2008;214:126&#x2013;135. doi: 10.1002/jcp.21168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.21168</ArticleId><ArticleId IdType="pubmed">17559060</ArticleId></ArticleIdList></Reference><Reference><Citation>Smittkamp S.E., Morris J.K., Bomhoff G.L., Chertoff M.E., Geiger P.C., Stanford J.A. SOD1-G93A Mice Exhibit Muscle-Fiber-Type-Specific Decreases in Glucose Uptake in the Absence of Whole-Body Changes in Metabolism. Neurodegener. Dis. 2013 doi: 10.1159/000351606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351606</ArticleId><ArticleId IdType="pmc">PMC3970434</ArticleId><ArticleId IdType="pubmed">24021858</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubiri I., Lombardi V., Bremang M., Mitra V., Nardo G., Adiutori R., Lu C.-H., Leoni E., Yip P., Yildiz O., et al. Tissue-Enhanced Plasma Proteomic Analysis for Disease Stratification in Amyotrophic Lateral Sclerosis. Mol. Neurodegener. 2018;13:60. doi: 10.1186/s13024-018-0292-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0292-2</ArticleId><ArticleId IdType="pmc">PMC6223075</ArticleId><ArticleId IdType="pubmed">30404656</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J.M., Marshall B.A., Mueckler M.M., McCaleb M., Amatruda J.M., Shulman G.I. Overexpression of Glut4 Protein in Muscle Increases Basal and Insulin-Stimulated Whole Body Glucose Disposal in Conscious Mice. J. Clin. Investig. 1995;95:429&#x2013;432. doi: 10.1172/JCI117673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI117673</ArticleId><ArticleId IdType="pmc">PMC295454</ArticleId><ArticleId IdType="pubmed">7814644</ArticleId></ArticleIdList></Reference><Reference><Citation>Leturque A., Loizeau M., Vaulont S., Salminen M., Girard J. Improvement of Insulin Action in Diabetic Transgenic Mice Selectively Overexpressing GLUT4 in Skeletal Muscle. Diabetes. 1996;45:23&#x2013;27. doi: 10.2337/diab.45.1.23.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.45.1.23</ArticleId><ArticleId IdType="pubmed">8522055</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao T.-S., Burcelin R., Katz E.B., Huang L., Charron M.J. Enhanced Insulin Action Due to Targeted GLUT4 Overexpression Exclusively in Muscle. Diabetes. 1996;45:28&#x2013;36. doi: 10.2337/diab.45.1.28.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.45.1.28</ArticleId><ArticleId IdType="pubmed">8522056</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Pradat P.-F., Ludolph A.C., Loeffler J.-P. Energy Metabolism in Amyotrophic Lateral Sclerosis. Lancet. Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacc&#xe0; F., Quarantelli M., Rinaldi C., Tucci T., Piro R., Perrotta G., Carotenuto B., Marsili A., Palma V., Michele G., et al. A Randomized Controlled Clinical Trial of Growth Hormone in Amyotrophic Lateral Sclerosis: Clinical, Neuroimaging, and Hormonal Results. J. Neurol. 2012;259:132&#x2013;138. doi: 10.1007/s00415-011-6146-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-011-6146-2</ArticleId><ArticleId IdType="pubmed">21706151</ArticleId></ArticleIdList></Reference><Reference><Citation>Massao Hirabara S., de Oliveira Carvalho C.R., Mendon&#xe7;a J.R., Piltcher Haber E., Fernandes L.C., Curi R. Palmitate Acutely Raises Glycogen Synthesis in Rat Soleus Muscle by a Mechanism That Requires Its Metabolization (Randle Cycle) FEBS Lett. 2003;541:109&#x2013;114. doi: 10.1016/S0014-5793(03)00316-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(03)00316-8</ArticleId><ArticleId IdType="pubmed">12706829</ArticleId></ArticleIdList></Reference><Reference><Citation>Puigserver P., Spiegelman B.M. Peroxisome Proliferator-Activated Receptor-&#x3b3; Coactivator 1&#x3b1; (PGC-1&#x3b1;): Transcriptional Coactivator and Metabolic Regulator. Endocr. Rev. 2003;24:78&#x2013;90. doi: 10.1210/er.2002-0012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/er.2002-0012</ArticleId><ArticleId IdType="pubmed">12588810</ArticleId></ArticleIdList></Reference><Reference><Citation>Thau N., Knippenberg S., Korner S., Rath K.J., Dengler R., Petri S. Decreased MRNA Expression of PGC-1&gt; and PGC-1&gt;YRegulated Factors in the SOD1G93A ALS Mouse Model and in Human Sporadic ALS. J. Neuropathol. Exp. Neurol. 2012;71:11. doi: 10.1097/NEN.0b013e318275df4b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318275df4b</ArticleId><ArticleId IdType="pubmed">23147503</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho Y., Hazen B.C., Russell A.P., Kralli A. Peroxisome Proliferator-Activated Receptor &#x3b3; Coactivator 1 (PGC-1)- and Estrogen-Related Receptor (ERR)-Induced Regulator in Muscle 1 (PERM1) Is a Tissue-Specific Regulator of Oxidative Capacity in Skeletal Muscle Cells. J. Biol. Chem. 2013;288:25207&#x2013;25218. doi: 10.1074/jbc.M113.489674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.489674</ArticleId><ArticleId IdType="pmc">PMC3757184</ArticleId><ArticleId IdType="pubmed">23836911</ArticleId></ArticleIdList></Reference><Reference><Citation>Cresci S., Wright L.D., Spratt J.A., Briggs F.N., Kelly D.P. Activation of a Novel Metabolic Gene Regulatory Pathway by Chronic Stimulation of Skeletal Muscle. Am. J. Physiol. Cell Physiol. 1996;270:C1413&#x2013;C1420. doi: 10.1152/ajpcell.1996.270.5.C1413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.1996.270.5.C1413</ArticleId><ArticleId IdType="pubmed">8967442</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulick T., Cresci S., Caira T., Moore D.D., Kelly D.P. The Peroxisome Proliferator-Activated Receptor Regulates Mitochondrial Fatty Acid Oxidative Enzyme Gene Expression. Proc. Natl. Acad. Sci. USA. 1994;91:11012&#x2013;11016. doi: 10.1073/pnas.91.23.11012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.23.11012</ArticleId><ArticleId IdType="pmc">PMC45156</ArticleId><ArticleId IdType="pubmed">7971999</ArticleId></ArticleIdList></Reference><Reference><Citation>Finck B.N., Bernal-Mizrachi C., Han D.H., Coleman T., Sambandam N., LaRiviere L.L., Holloszy J.O., Semenkovich C.F., Kelly D.P. A Potential Link between Muscle Peroxisome Proliferator- Activated Receptor-&#x3b1; Signaling and Obesity-Related Diabetes. Cell Metab. 2005;1:133&#x2013;144. doi: 10.1016/j.cmet.2005.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2005.01.006</ArticleId><ArticleId IdType="pubmed">16054054</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz S., Parone P.A., Lopes V.S., Lillo C., McAlonis-Downes M., Lee S.K., Vetto A.P., Petrosyan S., Marsala M., Murphy A.N., et al. Elevated PGC-1&#x3b1; Activity Sustains Mitochondrial Biogenesis and Muscle Function without Extending Survival in a Mouse Model of Inherited ALS. Cell Metab. 2012;15:778&#x2013;786. doi: 10.1016/j.cmet.2012.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2012.03.019</ArticleId><ArticleId IdType="pmc">PMC3565468</ArticleId><ArticleId IdType="pubmed">22560226</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J., Wu H., Tarr P.T., Zhang C.-Y., Wu Z., Boss O., Michael L.F., Puigserver P., Isotani E., Olson E.N., et al. Transcriptional Co-Activator PGC-1&#x3b1; Drives the Formation of Slow-Twitch Muscle Fibres. Nature. 2002;418:797&#x2013;801. doi: 10.1038/nature00904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature00904</ArticleId><ArticleId IdType="pubmed">12181572</ArticleId></ArticleIdList></Reference><Reference><Citation>Luquet S., Lopez-Soriano J., Holst D., Fredenrich A., Melki J., Rassoulzadegan M., Grimaldi P.A. Peroxisome Proliferator-activated Receptor &#x3b4; Controls Muscle Development and Oxydative Capability. FASEB J. 2003;17:2299&#x2013;2301. doi: 10.1096/fj.03-0269fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.03-0269fje</ArticleId><ArticleId IdType="pubmed">14525942</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y.-X., Zhang C.-L., Yu R.T., Cho H.K., Nelson M.C., Bayuga-Ocampo C.R., Ham J., Kang H., Evans R.M. Regulation of Muscle Fiber Type and Running Endurance by PPAR&#x3b4;. PLoS Biol. 2004;2:e294. doi: 10.1371/journal.pbio.0020294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0020294</ArticleId><ArticleId IdType="pmc">PMC509410</ArticleId><ArticleId IdType="pubmed">15328533</ArticleId></ArticleIdList></Reference><Reference><Citation>McVeigh J.J., Lopaschuk G.D. Dichloroacetate Stimulation of Glucose Oxidation Improves Recovery of Ischemic Rat Hearts. Am. J. Physiol.-Heart Circ. Physiol. 1990;259:H1079&#x2013;H1085. doi: 10.1152/ajpheart.1990.259.4.H1079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.1990.259.4.H1079</ArticleId><ArticleId IdType="pubmed">2221115</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse S., Randle P.J. Activation of Pyruvate Dehydrogenase in Perfused Rat Heart by Dichloroacetate (Short Communication) Biochem. J. 1973;134:651&#x2013;653. doi: 10.1042/bj1340651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj1340651</ArticleId><ArticleId IdType="pmc">PMC1177854</ArticleId><ArticleId IdType="pubmed">16742828</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel E., Cassina A., Mart&#xed;nez-Palma L., Bolatto C., Tr&#xed;as E., Gandelman M., Radi R., Barbeito L., Cassina P. Modulation of Astrocytic Mitochondrial Function by Dichloroacetate Improves Survival and Motor Performance in Inherited Amyotrophic Lateral Sclerosis. PLoS ONE. 2012;7:e34776. doi: 10.1371/journal.pone.0034776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034776</ArticleId><ArticleId IdType="pmc">PMC3318006</ArticleId><ArticleId IdType="pubmed">22509356</ArticleId></ArticleIdList></Reference><Reference><Citation>DeAngelo A.B., George M.H., House D.E. Hepatocarcinogenicity In The Male B6c3f1 Mouse Following A Lifetime Exposure To Dichloroacetic Acid In The Drinking Water: Dose-Response Determination And Modes Of Action. J. Toxicol. Environ. Health. 1999;58:485&#x2013;507. doi: 10.1080/009841099157115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/009841099157115</ArticleId><ArticleId IdType="pubmed">10632141</ArticleId></ArticleIdList></Reference><Reference><Citation>Lionetti V., Stanley W.C., Recchia F.A. Modulating Fatty Acid Oxidation in Heart Failure. Cardiovasc. Res. 2011;90:202&#x2013;209. doi: 10.1093/cvr/cvr038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvr038</ArticleId><ArticleId IdType="pmc">PMC3078800</ArticleId><ArticleId IdType="pubmed">21289012</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormack J.G., Stanley W.C., Wolff A.A. Ranolazine: A Novel Metabolic Modulator for the Treatment of Angina. Gen. Pharmacol. Vasc. Syst. 1998;30:639&#x2013;645. doi: 10.1016/S0306-3623(97)00301-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-3623(97)00301-7</ArticleId><ArticleId IdType="pubmed">9559312</ArticleId></ArticleIdList></Reference><Reference><Citation>Tafreshi M.J., Fisher E. Ranolazine: A New Approach to Management of Patients with Angina. Ann. Pharm. 2006;40:689&#x2013;693. doi: 10.1345/aph.1G367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1345/aph.1G367</ArticleId><ArticleId IdType="pubmed">16595572</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill J.A., Schofield R.S. The Use of Ranolazine in Cardiovascular Disease. Expert Opin. Investig. Drugs. 2002;11:117&#x2013;123. doi: 10.1517/13543784.11.1.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.11.1.117</ArticleId><ArticleId IdType="pubmed">11772326</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke B. Ranolazine Increases Active Pyruvate Dehydrogenase in Perfused Normoxic Rat Hearts: Evidence for an Indirect Mechanism. J. Mol. Cell. Cardiol. 1996;28:341&#x2013;350. doi: 10.1006/jmcc.1996.0032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmcc.1996.0032</ArticleId><ArticleId IdType="pubmed">8729066</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley W.C. Partial Fatty Acid Oxidation Inhibitors for Stable Angina. Expert Opin. Investig. Drugs. 2002;11:615&#x2013;629. doi: 10.1517/13543784.11.5.615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.11.5.615</ArticleId><ArticleId IdType="pubmed">11996644</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourouzis I., Mantzouratou P., Galanopoulos G., Kostakou E., Dhalla A.K., Belardinelli L., Pantos C. The Beneficial Effects of Ranolazine on Cardiac Function After Myocardial Infarction Are Greater in Diabetic Than in Nondiabetic Rats. J. Cardiovasc Pharm. 2014;19:457&#x2013;469. doi: 10.1177/1074248414524481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1074248414524481</ArticleId><ArticleId IdType="pubmed">24651516</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaitman B.R., Pepine C.J., Parker J.O., Skopal J., Chumakova G., Kuch J., Wang W., Skettino S.L., Wolff A.A. Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators Effects of Ranolazine with Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients with Severe Chronic Angina: A Randomized Controlled Trial. JAMA. 2004;291:309&#x2013;316. doi: 10.1001/jama.291.3.309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.291.3.309</ArticleId><ArticleId IdType="pubmed">14734593</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak K.R., Norman J., Mitchell J.R., Pinter M.J., Rich M.M. Sodium Channel Slow Inactivation as a Therapeutic Target for Myotonia Congenita. Ann. Neurol. 2015;77:320&#x2013;332. doi: 10.1002/ana.24331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24331</ArticleId><ArticleId IdType="pmc">PMC4315705</ArticleId><ArticleId IdType="pubmed">25515836</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Z., Zhao L., Chai W., Dong Z., Cao W., Liu Z. Ranolazine Recruits Muscle Microvasculature and Enhances Insulin Action in Rats: Ranolazine, Microvasculature and Insulin Action. J. Physiol. 2013;591:5235&#x2013;5249. doi: 10.1113/jphysiol.2013.257246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2013.257246</ArticleId><ArticleId IdType="pmc">PMC3810821</ArticleId><ArticleId IdType="pubmed">23798495</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckel R.H., Henry R.R., Yue P., Dhalla A., Wong P., Jochelson P., Belardinelli L., Skyler J.S. Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes. Diabetes Care. 2015;38:1189&#x2013;1196. doi: 10.2337/dc14-2629.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc14-2629</ArticleId><ArticleId IdType="pmc">PMC4477340</ArticleId><ArticleId IdType="pubmed">26049552</ArticleId></ArticleIdList></Reference><Reference><Citation>Caminiti G., Fossati C., Battaglia D., Massaro R., Rosano G., Volterrani M. Ranolazine Improves Insulin Resistance in Non-Diabetic Patients with Coronary Heart Disease. A Pilot Study. Int. J. Cardiol. 2016;219:127&#x2013;129. doi: 10.1016/j.ijcard.2016.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2016.06.003</ArticleId><ArticleId IdType="pubmed">27323337</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff A.A., Rotmensch H.H., Stanley W.C., Ferrari R. Metabolic Approaches to the Treatment of Ischemic Heart Disease: The Clinicians&#x2019; Perspective. Heart Fail. Rev. 2020;7:187&#x2013;203. doi: 10.1023/A:1015384710373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1015384710373</ArticleId><ArticleId IdType="pubmed">11988642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopaschuk G.D., Ussher J.R., Folmes C.D.L., Jaswal J.S., Stanley W.C. Myocardial Fatty Acid Metabolism in Health and Disease. Physiol. Rev. 2010;90:207&#x2013;258. doi: 10.1152/physrev.00015.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00015.2009</ArticleId><ArticleId IdType="pubmed">20086077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase. Circ. Res. 2000;86:580&#x2013;588. doi: 10.1161/01.RES.86.5.580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.86.5.580</ArticleId><ArticleId IdType="pubmed">10720420</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y.-H., Piao L., Hong Z., Toth P.T., Marsboom G., Bache-Wiig P., Rehman J., Archer S.L. Therapeutic Inhibition of Fatty Acid Oxidation in Right Ventricular Hypertrophy: Exploiting Randle&#x2019;s Cycle. J. Mol. Med. 2012;90:31&#x2013;43. doi: 10.1007/s00109-011-0804-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-011-0804-9</ArticleId><ArticleId IdType="pmc">PMC3249482</ArticleId><ArticleId IdType="pubmed">21874543</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraro E., Pin F., Gorini S., Pontecorvo L., Ferri A., Mollace V., Costelli P., Rosano G. Improvement of Skeletal Muscle Performance in Ageing by the Metabolic Modulator Trimetazidine: Metabolism Remodeling in Skeletal Muscle. J. CachexiaSarcopenia Muscle. 2016;7:449&#x2013;457. doi: 10.1002/jcsm.12097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.12097</ArticleId><ArticleId IdType="pmc">PMC4864287</ArticleId><ArticleId IdType="pubmed">27239426</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatta L., Vitiello L., Gorini S., Chiandotto S., Costelli P., Giammarioli A.M., Malorni W., Rosano G., Ferraro E. Modulating the Metabolism by Trimetazidine Enhances Myoblast Differentiation and Promotes Myogenesis in Cachectic Tumor-Bearing C26 Mice. Oncotarget. 2017;8:113938&#x2013;113956. doi: 10.18632/oncotarget.23044.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.23044</ArticleId><ArticleId IdType="pmc">PMC5768376</ArticleId><ArticleId IdType="pubmed">29371959</ArticleId></ArticleIdList></Reference><Reference><Citation>Karahan G., Kaya H., Erdogan M.A., Yigitturk G., Gokyayla E., Erbas O. Effects of Trimetazidine on Nerve Regeneration in a Rat Sciatic Nerve Injury Model. Bratisl. Lek. Listy. 2019;120:777&#x2013;782. doi: 10.4149/BLL_2019_130.</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/BLL_2019_130</ArticleId><ArticleId IdType="pubmed">31663354</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>